Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease

Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595–1607

Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149: 1514–1520

DeFronzo RA (1991) Insulin resistance syndrome. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194

International Diabetes Federation (online 14 April 2005) A new worldwide definition of the metabolic syndrome [ http://www.idf.org/home/index.cfm?unode=32EF2063-B966-468F-928C-A5682A4E3910 ] (accessed 13 September 2005)

Matsuzawa Y (1997) Pathophysiology and molecular mechanism of visceral fat syndrome: The Japanese case. Diabetes Metab Rev 13: 3–13

Despres JP et al. (1989) Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38: 304–309

Maeda K et al. (1997) Analysis of expression profile of genes in the human adipose tissue. Gene 190: 227–235

Matsuzawa Y et al. (2004) Adiponectin and metabolic syndrome. Arteroscler Thromb Vasc Biol 24: 29–33

Maeda K et al. (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286–289

Vague J (1956) The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 4: 20–34

Fujioka S et al. (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54–59

Hulthe J et al. (2003) Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52: 1612–1614

Evans DJ et al. (1984) Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal and insulin binding: Effect of obesity and body fat topography. J Clin Invest 74: 1515–1525

Yamashita S et al. (1996) Insulin resistance and body fat distribution. Diabetes Care 19: 287–291

Kanai H et al. (1990) Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16: 484–490

Larson B et al. (1984) Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in study of men born in 1913. BMJ 288: 1401–1410

Nakamura T et al. (1994) Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239–246

Nakamura T et al. (1997) Importance of intraabdominal fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int J Obes Relat Metab Disord 21: 580–586

Nakajima T et al. (1989) Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol 64: 369–373

Shinohara E et al. (1997) Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. J Intern Med 241: 11–18

Funahashi T et al. (1999) Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Inter Med 38: 202–206

Uysal KT et al. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389: 610–614

Shimomura I et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contribution to vascular disease in obesity. Nat Med 2: 800–803

Matsumoto S et al. (2002) Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun 292: 781–786

Matsuzawa Y (2005) Adipocytokines and metabolic syndrome. Semin Vasc Med 5: 34–39

Cigolini M et al. (1996) Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 16: 368–374

Fukuhara A et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–430

Hu E et al. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697–10703

Sherer EP et al. (1995) A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 270: 26746–26749

Arita Y et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83

Halleux CM et al. (2001) Secretion and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288: 1102–1107

Maeda N et al. (2001) PPARγ ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50: 2094–2099

Hotta K et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–1599

Stefan N et al. (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole body insulin sensitivity in humans. Diabetes 51: 1884–1888

Lindsay RS et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57–58

Maeda N et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731–737

Tomas E et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 90: 16309–16313

Iwashima Y et al. (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43: 1318–1323

Ouchi N et al. (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42: 231–234

Ouchi N et al. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473–2476

Zoccali C et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134–141

Kumada M et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: 85–89

Pischon T et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730–1737

Kondo H et al. (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51: 2325–2328

Okamoto Y et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 26: 2767–2770

Matsuda M et al. (2002) Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 277: 37487–37491

Okamoto Y et al. (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32: 47–50

Ouchi N et al. (2000) Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through c-AMP dependent pathway. Circulation 102: 1296–1301

Arita Y et al. (2002) Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105: 2893–2898

Ouchi N et al. (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057–1063

Kumada M et al. (2004) Adiponectin specifically increases tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109: 2046–2049

Shibata R et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384–1389

Kobayashi H et al. (2004) Selective suppression of endothelial cell apotosis by high molecular weight form of adiponectin. Circ Res 94: e27–e31

Fisher FF et al. (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian Males. Diabetologia 48: 1084–1087

Hug C et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308–10313

Yamauchi T et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769

Nishizawa H et al. (2002) Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor γ transactivation. J Biol Chem 277: 1586–1592